ELV
Elevance Health Inc.
ELV's fundamentals are mixed: free cash flow grew 73%, but its operating margin fell 1 points to 2.7%. At 18x earnings, it's trading in line with its usual 18x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ELV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Stable |
ELV's cash flow is currently healthy, and its revenue, profitability and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ELV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $333 | -22% |
| Forward | 15x | $430 | — |
| Fair | 18x | $416 | -3.3% |
| Current | 18x | $430 | — |
| Expensive | 20x | $470 | +9.4% |
Historical ranges are pointers, not guarantees.
ELV's PE is in its fair range at 18x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ELV Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Moderate | |
| Low |
Analysts expect ELV's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ELV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $28.82 | +22% |
| Q3 2026 | $23.54 | -4% |
| Q2 2026 | $22.59 | -4.2% |
| Q1 2026 | $23.60 | -8.2% |
| Q4 2025 | $25.21 | -1.8% |
| Q3 2025 | $24.53 | -11% |
| Q2 2025 | $23.57 | -18% |
| Q1 2025 | $25.70 | -3.1% |
| Q4 2024 | $25.68 | +1.8% |
ELV has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ELV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $51.4B | +1.4% |
| Q2 2026 | $50.5B | +1.4% |
| Q1 2026 | $50.2B | +2.6% |
| Q4 2025 | $49.7B | +9.5% |
| Q3 2025 | $50.7B | +12% |
| Q2 2025 | $49.8B | +13% |
| Q1 2025 | $48.9B | +15% |
| Q4 2024 | $45.4B | +6.6% |
ELV's revenue has grown year over year every quarter since late 2020: $51.4B last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.5% | -0.1 points |
| Q2 2026 | 3.5% | -1.4 points |
| Q1 2026 | 4.2% | -2.3 points |
| Q4 2025 | 0.6% | -0.9 points |
| Q3 2025 | 2.5% | -0.6 points |
| Q2 2025 | 4.9% | -1.4 points |
| Q1 2025 | 6.5% | -0.6 points |
| Q4 2024 | 1.5% | -1.5 points |
ELV has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ELV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ELV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1B | +29% |
| Q2 2026 | $1.6B | -9% |
| Q1 2026 | $4.1B | +399% |
| Q4 2025 | -$209M | -154% |
| Q3 2025 | $775M | -67% |
| Q2 2025 | $1.8B | +1341% |
| Q1 2025 | $821M | -52% |
| Q4 2024 | $384M | +$3.7B |
ELV still generates free cash flow, though less than at its 2023 peak: $6.5B over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ELV on cash flow, with more consistent year-over-year improvement.
ELV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -300K shares |
| 1 year | -2.7% | -6.1M shares |
| 3 years | -8% | -18.9M shares |
| 5 years | -12% | -28.4M shares |
| Available history | -16% | -42.7M shares |
ELV has 218M diluted shares, down 2.7% from a year ago, with $2.2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $330M |
| Q2 2026 | $234M |
| Q1 2026 | $1.1B |
| Q4 2025 | $471M |
| Q3 2025 | $876M |
| Q2 2025 | $378M |
| Q1 2025 | $880M |
| Q4 2024 | $1.8B |
ELV spent $2.2B buying back its own shares over the past year, down 45% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ELV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ELV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.6x | Moderate |
ELV's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ELV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.8 | Neutral |
| Stochastic | 68.7 | Neutral |
ELV's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ELV PE vs Healthcare Sector
| Metric | ELV | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 57 | 29 | 28 pts above |
ELV is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ELV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $417.4 | 3% above |
| 20 week MA | $406.3 | 5.8% above |
| 50 week MA | $373.0 | 15% above |
| 100 week MA | $368.4 | 17% above |
| 200 week MA | $424.7 | 1.2% above |
ELV has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ELV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $306.4 | $308.7 | +0.7% |
| 2021 | $308.7 | $455.7 | +48% |
| 2022 | $455.7 | $514.3 | +13% |
| 2023 | $514.3 | $471.6 | -8.3% |
| 2024 | $471.6 | $371.1 | -21% |
| 2025 | $371.1 | $349.9 | -5.7% |
| 2026 YTD | $349.9 | $429.9 | +23% |
ELV has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.